HemostOD

Executive Summary

HemostOD is a Swiss preclinical-stage biotech company developing a proprietary platform to engineer and manufacture universal, HLA-low platelets. Founded in 2020 and based at EPFL Innovation Park in Lausanne, the company addresses critical unmet needs in thrombocytopenia treatment, tissue-targeted cargo delivery, regenerative medicine, and cell culture enhancement. By creating universally compatible platelets with reduced immunogenicity, HemostOD aims to transform platelet transfusion therapy and enable targeted delivery of therapeutic payloads. Currently at the preclinical stage, the company is focused on platform validation and advancing toward IND-enabling studies. With no disclosed funding rounds, HemostOD likely relies on grants or early-stage investors. The technology holds promise but faces typical early-stage risks including manufacturing scale-up and clinical translation. Success depends on completing preclinical proof-of-concept and securing partnerships or Series A financing.

Upcoming Catalysts (preview)

• H2 2026Preclinical proof-of-concept data in thrombocytopenia model60% success
• H1 2027Series A financing or grant award40% success
• H2 2027Partnership with pharma for cargo delivery platform30% success